Advertisement

The Economic Impact of HA-1A (Centoxin) Against Endotoxin

  • 6 Accesses

  • 6 Citations

Summary

Monoclonal antibodies have been shown to reduce morbidity and mortality in selected subsets of patients with Gram-negative sepsis and/or septic shock. However, the acquisition costs of the antibody products are expected to be in the range of $US3500 to $US4000 per course of therapy and precise identification of patients who will benefit may be difficult. Therefore, the economic impact of these antibodies will be significant. We have performed a model cost-effectiveness and cost-benefit analysis specific to our institution based on previously reported mortality figures. Our data suggest that the cost-effectiveness of HA-1A (Centoxin®) will be comparable with that of a variety of commonly used medical interventions, but will produce an incremental increase in costs of at least $US7000 per patient because of the acquisition cost of the drug. as well as an increase in numbers of survivors whose hospitalisation will be prolonged.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 49.95

Price includes VAT for USA

References

  1. Barriere SL, Guglielmo BJ. Gram-negative sepsis. The sepsis syndrome, and the role of antiendotoxin monoclonal antibodies. Clinical Pharmacy 11(3): 223–235, 1992

  2. Baumgartner JD. Immunotherapy with antibodies to core lipopolysaccharide: a critical appraisal. Infectious Diseases Clinics of North America 5(4): 915–927, 1991

  3. Bone RC. A critical evaluation of new agents for the treatment of sepsis. Journal of the American Medical Association 266(12): 1686–1691, 1991

  4. Greenman RL, Schein RMH, Martin MA, Wenzel RP, MacIntyre NR, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. Journal of the American Medical Association 266(8): 1097–1102, 1991

  5. Nash DB, Johnson NE, Gottlieb JE, Vlasses PH. Monoclonal antibodies for septic shock: in or out of the barn door? Quality Review Bulletin 11(10): 310–313, 1991

  6. Oster G, Tuden RL, Colditz GA. A cost-effectiveness analysis of prophylaxis against deep-venous thrombosis in major orthopedic surgery. Journal of the American Medical Association 257: 203–208, 1987

  7. Oster G, Epstein AM. Cost-effectiveness of antihyperlipidemic therapy in the prevention of coronary heart disease. Journal of the American Medical Association 258: 2381–2387, 1987

  8. Schulman KA, Glick HA, Rubin H, Eisenberg JM. Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis. Journal of the American Medical Association 266(24): 3466–3471, 1991

  9. Udvarhelyi IS, Colditz GA, Rai A, Epstein AM. Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly? Annals of Internal Medicine 116(3): 238–244, 1992

  10. van Deventer SJ, Buller HR, Ten Cate JW. Endotoxemia: an early predictor of septicemia in febrile patients. Lancet 1: 605–609, 1988

  11. Wenzel R, Bone R, Fein A, Quenzer R, Schentag J, et al. Results of a second double-blind, randomized controlled trial of antiendotoxin antibody E5 in Gram-negative sepsis. Progress Abstracts of the 31st Interscience Conference on Antimicrobial Agents in Chemotherapy, Abstract 1170, American Society for Microbiology, Washington DC; Oct 2, 1991

  12. Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sadoff JC, et al. Treatment of Gram-negative bacteraemia and septic shock with HA-1A human monoclonal antibody against endotoxin. New England Journal of Medicine 324(7): 429–436, 1991

Download references

Author information

Correspondence to Dr Steven L. Barriere.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Barriere, S.L. The Economic Impact of HA-1A (Centoxin) Against Endotoxin. PharmacoEconomics 2, 408–413 (1992). https://doi.org/10.2165/00019053-199202050-00008

Download citation

Keywords

  • Septic Shock
  • Organ System Dysfunction
  • UCLA Medical
  • Actual Patient Data
  • Pharmacoeconomic Eval